With few real-life studies that have specifically focused on how atopic dermatitis (AD) affects patients living with the ...

Dupilumab in patients with diffuse type 2 CRSwNP had beneficial changes in nasal passage microbiota but did not alter gastrointestinal microbiota.

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Patients with AD treated with dupilumab have a lower risk of various infections than those treated with methotrexate or cyclosporine.

Key Takeaways A new evidence review highlights the best treatments for hivesInjectable antibody drugs omalizumab and ...

Patients with moderate to severe atopic dermatitis experienced a 71% decrease in Eczema Area and Severity Index scores from ...

Chronic rhinosinusitis with nasal polyps increases the likelihood of developing coexisting conditions, such as asthma, underscoring the need for more effective, comprehensive treatments.

Patients with atopic dermatitis experienced improvements in severity with 16 weeks of tralokinumab despite the number of ...

Introducing lebrikizumab for severe atopic dermatitis in Italy may result in cost savings for the national health system, a ...

When Chloe Tatton boarded a flight to relocate to Dubai early last year, she hoped the change of climate might help ease her ...

Prescription volume for specialty medications, not price hikes, largely seems to be the main factor in the ongoing huge ...

A new international study led by researchers at McMaster University has identified the most effective and safest treatments ...